CytoMed Therapeutics Limited Ordinary Shares (GDTC) - Net Assets
Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) has net assets worth $6.85 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.98 Million) and total liabilities ($1.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GDTC intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.85 Million |
| % of Total Assets | 85.83% |
| Annual Growth Rate | 23.45% |
| 5-Year Change | 163.84% |
| 10-Year Change | N/A |
| Growth Volatility | 682.26 |
CytoMed Therapeutics Limited Ordinary Shares - Net Assets Trend (2019–2025)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of CytoMed Therapeutics Limited Ordinary Sh to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below shows the annual net assets of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. For live valuation and market cap data, see market value of CytoMed Therapeutics Limited Ordinary Sh.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.85 Million | -24.20% |
| 2024-12-31 | $9.04 Million | -19.81% |
| 2023-12-31 | $11.27 Million | +1814.17% |
| 2022-12-31 | $589.03K | -77.32% |
| 2021-12-31 | $2.60 Million | +444.78% |
| 2020-12-31 | $476.83K | -75.37% |
| 2019-12-31 | $1.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CytoMed Therapeutics Limited Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1773820800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.66 Million | 376.76% |
| Other Comprehensive Income | $604.90K | 9.24% |
| Other Components | $111.22K | 1.70% |
| Total Equity | $6.54 Million | 100.00% |
CytoMed Therapeutics Limited Ordinary Shares Competitors by Market Cap
The table below lists competitors of CytoMed Therapeutics Limited Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
$12.62 Million |
|
BTM Resources Bhd
KLSE:7188
|
$12.62 Million |
|
Par Drugs And Chemicals Limited
NSE:PAR
|
$12.62 Million |
|
Tractial S.A.
PA:ALTRA
|
$12.62 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
$12.60 Million |
|
Personas Social Inc
V:PRSN
|
$12.56 Million |
|
Lanthanein Resources Ltd
AU:LNR
|
$12.55 Million |
|
NFL Biosciences SAS
PA:ALNFL
|
$12.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CytoMed Therapeutics Limited Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,964,069 to 6,544,446, a change of -2,419,623 (-27.0%).
- Net loss of 3,916,834 reduced equity.
- New share issuances of 283,094 increased equity.
- Other comprehensive income increased equity by 584,684.
- Other factors increased equity by 629,433.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.92 Million | -59.85% |
| Share Issuances | $283.09K | +4.33% |
| Other Comprehensive Income | $584.68K | +8.93% |
| Other Changes | $629.43K | +9.62% |
| Total Change | $- | -26.99% |
Book Value vs Market Value Analysis
This analysis compares CytoMed Therapeutics Limited Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.10x to 1.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.35 | $1.08 | x |
| 2020-12-31 | $0.08 | $1.08 | x |
| 2021-12-31 | $0.37 | $1.08 | x |
| 2022-12-31 | $0.07 | $1.08 | x |
| 2023-12-31 | $1.06 | $1.08 | x |
| 2024-12-31 | $0.78 | $1.08 | x |
| 2025-12-31 | $0.56 | $1.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CytoMed Therapeutics Limited Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1227.07%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.22x
- Recent ROE (-59.85%) is above the historical average (-167.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -44.36% | 0.00% | 0.00x | 1.52x | $-1.05 Million |
| 2020 | -407.14% | -4323.24% | 0.01x | 8.02x | $-1.99 Million |
| 2021 | -79.82% | -2463.45% | 0.01x | 2.35x | $-2.33 Million |
| 2022 | -518.13% | -835.73% | 0.07x | 8.91x | $-3.11 Million |
| 2023 | -36.75% | -813.99% | 0.04x | 1.10x | $-5.27 Million |
| 2024 | -28.68% | -3699.67% | 0.01x | 1.12x | $-3.47 Million |
| 2025 | -59.85% | -1227.07% | 0.04x | 1.22x | $-4.57 Million |
Industry Comparison
This section compares CytoMed Therapeutics Limited Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $6.85 Million | -44.36% | 0.17x | $12.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more